Does Omnitrope Help Growth?
Omnitrope (somatropin) is a recombinant human growth hormone approved by the FDA to treat growth hormone deficiency (GHD) in children, where it increases height velocity and helps children reach normal adult height.[1] Clinical trials show treated GHD children gain 7-12 cm more height than untreated peers over several years.[2]
How Does Omnitrope Promote Growth?
It mimics natural growth hormone by stimulating insulin-like growth factor 1 (IGF-1) production in the liver, which drives bone elongation, cartilage growth, and protein synthesis. Injections (daily subcutaneous) are dosed by body weight, typically 0.16-0.24 mg/kg/week for children.[1][3]
What Conditions Is It Approved For?
- Pediatric GHD (primary use for growth).
- Turner syndrome.
- Prader-Willi syndrome.
- Chronic kidney disease (pre-transplant).
- Idiopathic short stature (ISS) in children below -2.25 standard deviations, where it provides modest height gains (4-7 cm).[1][4]
Not approved for idiopathic short stature in all regions or for non-medical short stature.
How Much Growth Can Kids Expect?
Response varies by age, bone age, and diagnosis:
| Condition | Average Height Gain |
|-----------|---------------------|
| GHD | 8-10 cm final height increase [2] |
| Turner syndrome | 5-7 cm [4] |
| ISS | 3-7 cm [1] |
Treatment starts before puberty ends, ideally under age 12 for boys and 10 for girls, lasting 2-5+ years until growth plates close.[3]
Does It Work for Healthy Short Kids?
Limited evidence for non-GHD short stature; FDA approval for ISS is narrow. Studies show smaller gains and no benefit post-puberty.[4] Off-label use occurs but lacks strong data.
What Are Common Side Effects?
Mild: Injection site reactions, headaches, joint pain (10-20% of patients).[1] Rare risks: Slipped capital femoral epiphysis, hyperglycemia, increased intracranial pressure. Long-term: Slight cancer risk elevation in predisposed patients; monitor IGF-1 levels.[3]
How Long Until Results and Treatment Duration?
Visible growth acceleration in 3-6 months; peak velocity year 1-2. Continue until adult height reached or growth plates fuse (assessed by X-ray).[2]
Cost and Access Issues
Annual cost: $20,000-$40,000 USD, often covered by insurance for approved uses. Generic versions (e.g., from Sandoz, Omnitrope's maker) lowered prices since 2006 patent expiry.[5] Patient assistance programs available via manufacturer.
[1]: FDA Label for Omnitrope
[2]: New England Journal of Medicine trial on GHD
[3]: Endocrine Society Guidelines
[4]: Pediatrics review on ISS
[5]: DrugPatentWatch: Omnitrope